Multiple Myeloma medicine: Natco Pharma unveils Pomalidomide under brand NAT-POMALIDOMIDE in Canada

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. It is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). Its focus is primarily on niche therapeutic areas and complex products. Natco markets and distributes products in over 40 countries. The company sells its FDF products in the United States, India, Europe, and the rest of the world (“RoW”).

Read also: Natco Pharma unveils Chlorantraniliprole (CTPR) formulated product NATGEN in India

Natco Pharma manufactures API products which are primarily used for captive consumption in the company's FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, the company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. Natco has eight manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.